NASDAQ:UROV Urovant Sciences (UROV) Stock Price, News & Analysis → How a $0.25 cent option contract makes my top traders feel (From DTI) (Ad) Free UROV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$16.24▼$16.2450-Day Range$16.19▼$16.2452-Week Range$7.15▼$16.26VolumeN/AAverage Volume114,469 shsMarket Capitalization$531.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Urovant Sciences alerts: Email Address Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Urovant Sciences Stock (NASDAQ:UROV)Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.Read More Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. UROV Stock News HeadlinesApril 26, 2024 | finanznachrichten.dePierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA(vibegron) in overactive bladder syndromeApril 26, 2024 | finance.yahoo.comPierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndromeApril 28, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.March 26, 2024 | finance.yahoo.comA2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of DirectorsDecember 6, 2023 | finance.yahoo.comPetauri™ Elects William Fleming and James Robinson to Its Board of DirectorsOctober 4, 2023 | finance.yahoo.comPM360 Announces 2023 Trailblazer Award WinnersSeptember 11, 2023 | finance.yahoo.comEledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of DirectorsJuly 31, 2023 | finance.yahoo.comCNVCF - BioHarvest Sciences Inc.April 28, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.July 25, 2023 | businesswire.comUroGen Pharma Announces the Appointment of James Robinson to its Board of DirectorsJuly 20, 2023 | benzinga.comBenign Prostatic Hyperplasia Therapeutics Market Size Predictions suggest a rise of 5.1% CAGR, to reach value of USD 12.9 Billion by 2032June 24, 2023 | npr.orgKPCW Cool Science RadioJune 9, 2023 | uk.finance.yahoo.comOveractive Bladder Treatment Global Market Report 2023May 22, 2023 | finanznachrichten.dePierre Fabre announces start of EU marketing authorization application procedure for Vibegron in overactive bladderMay 3, 2023 | bizjournals.comThree Japanese pharma subsidiaries to lay off 223 in MarlboroughMarch 28, 2023 | finance.yahoo.comOveractive Bladder Market to Grow Rapidly at a Considerable CAGR During the Forecast Period (2023–2032) | DelveInsightFebruary 19, 2023 | marketwatch.comDrugs for Enuresis Market 2023: Growth by 2029 Top Players with OpportunitiesJanuary 19, 2023 | technews.tmcnet.comUrovant Sciences® Announces Collaboration with Holly Robinson Peete to Help Raise Awareness for Overactive Bladder and Treatment OptionsJanuary 16, 2023 | marketwatch.comDrugs for Enuresis Market Share From 2023 To 2029 And Unlimited Opportunities for New Companies and Latest DevelopmentsDecember 21, 2022 | msn.comHow To Deal With An Overactive Bladder If You're Traveling Long Distance Over The HolidaysDecember 20, 2022 | seekingalpha.comRoivant Sciences: A Solid Year Of Progress And Good Prospects For 2023October 27, 2022 | finance.yahoo.comUrovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed TabletOctober 4, 2022 | seekingalpha.comMyovant: Sumitomo Bid Is A Head Scratcher, Where Is The Value?September 30, 2022 | financialpost.com'I lose money every time I leave the house': Inflation complicates back-to-office pushSeptember 26, 2022 | investopedia.comSocial Science: What It Is and the 5 Major BranchesSeptember 13, 2022 | usnews.comBest Global Universities for Computer ScienceSeptember 10, 2022 | npr.orgScience FridaySee More Headlines Receive UROV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Urovant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/11/2021Today4/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:UROV CUSIPN/A CIK1740547 Webwww.urovant.com Phone44-0-20-7400-3347FaxN/AEmployees70Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-146,740,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-162.90% Debt Debt-to-Equity RatioN/A Current Ratio2.91 Quick Ratio2.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.90) per share Price / Book-8.55Miscellaneous Outstanding Shares32,743,000Free FloatN/AMarket Cap$531.75 million OptionableNot Optionable Beta2.36 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. James A. Robinson Jr. (Age 50)Pres, CEO & Director Comp: $1.07MMr. Ajay Bansal (Age 59)CFO & Sr. VP of Bus. Devel. Comp: $558.34kDr. Cornelia Haag-Molkenteller M.D. (Age 62)Ph.D., Chief Medical Officer of USI Comp: $629.79kMs. Christine G. Ocampo (Age 49)Chief Accounting Officer & Sr. VP Ryan KubotaExec. Director of Investor RelationsMr. Bryan E. Smith (Age 42)Gen. Counsel Dr. David HovlandSr. VP of Global Regulatory AffairsMr. Kenton StewartSr. VP of Market AccessMore ExecutivesKey CompetitorsPhathom PharmaceuticalsNASDAQ:PHATAstria TherapeuticsNASDAQ:ATXSArriVent BioPharmaNASDAQ:AVBPAltimmuneNASDAQ:ALTStoke TherapeuticsNASDAQ:STOKView All Competitors UROV Stock Analysis - Frequently Asked Questions How were Urovant Sciences' earnings last quarter? Urovant Sciences Ltd. (NASDAQ:UROV) posted its quarterly earnings data on Thursday, February, 11th. The company reported ($1.46) earnings per share for the quarter, topping the consensus estimate of ($1.59) by $0.13. What other stocks do shareholders of Urovant Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Urovant Sciences investors own include Fulcrum Therapeutics (FULC), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), AVEO Pharmaceuticals (AVEO), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Provention Bio (PRVB), SCYNEXIS (SCYX) and Xeris Biopharma (XERS). When did Urovant Sciences IPO? Urovant Sciences (UROV) raised $150 million in an IPO on Thursday, September 27th 2018. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO. This page (NASDAQ:UROV) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urovant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
